<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2619">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04398303</url>
  </required_header>
  <id_info>
    <org_study_id>AHS 20-03</org_study_id>
    <nct_id>NCT04398303</nct_id>
  </id_info>
  <brief_title>ACT-20 in Patients With Severe COVID-19 Pneumonia</brief_title>
  <official_title>A Phase 1/2 Randomized, Placebo-Controlled Trial of ACT-20 in Patients With Severe COVID-19 Pneumonia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aspire Health Science</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aspire Health Science</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is determine the safety and efficacy of ACT-20-MSC&#xD;
      (allogenic human umbilical derived mesenchymal stem cells) and ACT-20-CM (allogenic human&#xD;
      umbilical derived mesenchymal stem cells in conditioned media) in patients with moderate to&#xD;
      severe COVID-19 pneumonia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will assess the safety and efficacy of ACT-20-MSC and ACT-20-CM administered&#xD;
      intravenously to subjects with moderate to severe COVID-19 related pneumonia in two parts.&#xD;
&#xD;
      Part 1 is an open-label study of 10 subjects, 5 with moderate COVID-19 pneumonia and 5 with&#xD;
      severe COVID-19 pneumonia. Of these 10 subjects, 5 will receive ACT-20-CM and 5 will receive&#xD;
      ACT-20-MSC resuspended in ACT-20-CM.&#xD;
&#xD;
      Part 2 is a randomized, blinded, placebo-controlled study of 60 patients, 30 with moderate&#xD;
      COVID-19 pneumonia and 30 with severe COVID-19 pneumonia. Randomization will be 1:1:1&#xD;
      ACT-20-MSC in ACT-20-CM, ACT-20-CM or placebo. The placebo is MEM-α, a widely used sterile&#xD;
      culture media that contains non-essential amino acids, nucleosides, vitamins, glucose, sodium&#xD;
      pyruvate and lipoic acid.&#xD;
&#xD;
      Subjects treated at each investigative site will provide written informed consent prior to&#xD;
      the conduct of any study-related procedures. Thereafter, they will be screened and those&#xD;
      meeting the inclusion/exclusion criteria will be enrolled into the trial and undergo all the&#xD;
      study procedures including the intravenous administration of the investigational medical&#xD;
      product (IMP = ACT-20-MSC in ACT-20-CM or ACT-20-CM) or placebo. The IMP will be administered&#xD;
      in addition to any standard of care treatment the subject is receiving.&#xD;
&#xD;
      Subjects will be assessed daily while in hospital. Following discharge from hospital,&#xD;
      subjects will be following for an additional three month period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2020</start_date>
  <completion_date type="Anticipated">October 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mortality at day 30</measure>
    <time_frame>30 days post treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ventilated Subjects - Ventilator Free Days</measure>
    <time_frame>28 days post treatment</time_frame>
    <description>Number of ventilator-free days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilated Subjects - Improvement in Ventilator Settings</measure>
    <time_frame>28 days post treatment, or until off of ventilator</time_frame>
    <description>Improvement in ventilator settings: Minute ventilation, PEEP, FiO2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High-Flow O2 Support Subjects - Step-Down O2 Therapy</measure>
    <time_frame>30 days post treatment, or until off of high-flow O2 support</time_frame>
    <description>Days of step-down O2 therapy as evidenced by: improvement in required volume, change to nasal cannula or face mask delivery or improvement in required concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High Flow O2 Support Subjects - Respiration Rate</measure>
    <time_frame>30 days post treatment, or until off of high-flow O2 support</time_frame>
    <description>Respiration Rate &lt; 30 for &gt; 24 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Both Ventilated and High-Flow O2 Support Subjects - ICU-Free Days</measure>
    <time_frame>30 days post treatment, or until off of ventilator or high-flow O2 support</time_frame>
    <description>Number of ICU-free days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Both Ventilated and High-Flow O2 Support Subjects - Pulmonary Function Improvement</measure>
    <time_frame>30 days post treatment, or until off of ventilator or high-flow O2 support</time_frame>
    <description>Improvement in pulmonary function as evidenced by A-A oxygen gradient, O2 saturation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Both Ventilated and High-Flow O2 Support Subjects - Increased Berlin Score</measure>
    <time_frame>30 days post treatment, or until off of ventilator or high-flow O2 support</time_frame>
    <description>Increased Berlin Criteria score &gt; 24 hours</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>COVID-19 Pneumonia</condition>
  <arm_group>
    <arm_group_label>ACT-20-MSC in ACT-20-CM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Conventional treatment plus ACT-20-MSC in ACT-20-CM administered intravenously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ACT-20-CM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Conventional treatment plus ACT-20-CM administered intravenously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Conventional treatment plus placebo (MEM-α) administered intravenously</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ACT-20-MSC</intervention_name>
    <description>1 million cells / kg body weight in 100 ml in conditioned media</description>
    <arm_group_label>ACT-20-MSC in ACT-20-CM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ACT-20-CM</intervention_name>
    <description>100 ml of conditioned media only</description>
    <arm_group_label>ACT-20-CM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>100 ml of MEM-α</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female patients age 18 to 85, inclusive&#xD;
&#xD;
          2. Confirmed positive test for COVID-19 by standard reverse transcriptase polymerase&#xD;
             chain reaction (RT-PCR) assay or equivalent&#xD;
&#xD;
          3. On mechanical ventilation (n=35), or high-flow O2 support (n=35) and:&#xD;
&#xD;
               1. Disease severity level of &quot;moderate&quot; (PaO2/FiO2 of 100-200) (n=35), or &quot;severe&quot;&#xD;
                  (PaO2/FiO2 &lt; 100) (n=35) as established using the Berlin Criteria for ARDS&#xD;
                  (Barbas, Isola &amp; Caser, 2014; Baron &amp; Levy, 2016).&#xD;
&#xD;
               2. Positive end-expiratory airway pressure (PEEP) ≥ 5 cmH2O&#xD;
&#xD;
               3. Oxygen saturation ≤ 93%&#xD;
&#xD;
          4. Non-cardiogenic bilateral pulmonary edema on frontal chest radiograph that cannot be&#xD;
             explained by effusion, collapsed lung or lung nodule&#xD;
&#xD;
          5. Able to understand and provide voluntary informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Unable to understand and provide voluntary informed consent&#xD;
&#xD;
          2. Current infection with HIV-1, HIV-2, Hepatitis B, Hepatitis C or HTLV&#xD;
&#xD;
          3. History of malignancy, other than non-melanoma skin cancer or non-metastatic prostate&#xD;
             cancer&#xD;
&#xD;
          4. Currently receiving extracorporeal life support or high-frequency oscillatory&#xD;
             ventilation&#xD;
&#xD;
          5. Weight &gt; 150 kg&#xD;
&#xD;
          6. Current severe chronic respiratory disease, as demonstrated by:&#xD;
&#xD;
               1. PaCO2 &gt; 50 mm Hg, or&#xD;
&#xD;
               2. history of use of home oxygen&#xD;
&#xD;
          7. Major trauma within the past 7 days&#xD;
&#xD;
          8. Lung transplant recipient&#xD;
&#xD;
          9. WHO Class III or IV pulmonary hypertension&#xD;
&#xD;
         10. Documented deep vein thrombosis or pulmonary embolism within the past 3 months&#xD;
&#xD;
         11. Currently pregnant or lactating&#xD;
&#xD;
         12. Currently participating in another clinical trial, or participation in another&#xD;
             clinical trial within 30 days of enrollment&#xD;
&#xD;
         13. Hypersensitivity to Dextran-40 or Dimethyl Sulfoxide (DMSO)&#xD;
&#xD;
         14. Current pharmacotherapy using hydroxychloroquine or Interleukin-6 inhibitors&#xD;
&#xD;
         15. History of CVA or MI within 180 days of study enrollment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Laura Fairbairn</last_name>
    <phone>403-921-5854</phone>
    <email>regulatory@aspire2cure.com</email>
  </overall_contact>
  <link>
    <url>http://aspire2cure.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 20, 2020</study_first_submitted>
  <study_first_submitted_qc>May 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 21, 2020</study_first_posted>
  <last_update_submitted>May 20, 2020</last_update_submitted>
  <last_update_submitted_qc>May 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Stem cells</keyword>
  <keyword>Pneumonia</keyword>
  <keyword>COVID</keyword>
  <keyword>COVID-19</keyword>
  <keyword>Coronavirus</keyword>
  <keyword>SARS-CoV-2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

